CoChat

Cardiovascular effects and safety of (non-aspirin) NSAIDs

Schjerning, Anne-Marie, McGettigan, Patricia, Gislason, Gunnar · 2020 · Nature Reviews Cardiology

The DOI matches its Crossref record; 113 of the 116 references it cites were found in a registry or an index.

Abstract

Nonsteroidal anti-inflammatory drugs (NSAIDs) are effective, widely used analgesics. For the past 2 decades, considerable attention has been focused on their cardiovascular safety. After early studies indicating an association between NSAID use and increased risks of heart failure and elevated blood pressure, subsequent studies found a link between NSAID use and an increased risk of thrombotic events. Selective cyclooxygenase 2 (COX2) inhibitors (also known as coxibs) have been associated with the greatest risk of adverse vascular effects but concern also relates to non-selective NSAIDs, especially those with strong COX2 inhibition such as diclofenac. Although NSAID use is discouraged in patients with cardiovascular disease, pain-relief medication is often required and, in the absence of analgesics that are at least as effective but safer, NSAIDs are frequently prescribed. Furthermore, non-prescription use of NSAIDs, even among people with underlying cardiovascular risks, is largely unsupervised and varies widely between countries. As concern mounts about the disadvantages of alternatives to NSAIDs (such as opioids) for pain management, the use of NSAIDs is likely to rise. Given that the pharmaceutical development pipeline lacks new analgesics, health-care professionals, patients and medicine regulatory authorities are focused on optimizing the safe use of NSAIDs. In this Review, we summarize the current evidence on the cardiovascular safety of NSAIDs and present an approach for their use in the context of holistic pain management.

Overview

Integrity signals

Registry

Crossref · 10.1038/s41569-020-0366-z

Cites

113 of 113 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 113 references

Research works printed but not linked: 1

  1. BioSpace. Galt Pharmaceuticals receives FDA priority review for non-controlled pain management drug, orphengesic forte, an opioid-free alternative for patients. BioSpace https://www.biospace.com/article/releases/galt-pharmaceuticals-receives-fda-priority-review-for-non-controlled-pain-management-drug-orphengesic-forte-an-opioid-free-alternative-for-patients/ (2019).

Cited by

See all 417

Metadata

Authors
Schjerning, A.-M., McGettigan, P., & Gislason, G.
Affiliations
  • Zealand University Hospital (DK)
  • Queen Mary University of London (GB)
  • University of Copenhagen (DK)
Corresponding author
Gislason, Gunnar
Venue
Nature Reviews Cardiology
Published
2020-04-22
Volume
17
Issue
9
Pages
574-584
ISSN
  • 1759-5002 (ISSN-L)
  • 1759-5010
OpenAlex
W3020716837
Cited by
387
References
116
Citations by year
2026: 52 · 2025: 76 · 2024: 82 · 2023: 68 · 2022: 69 · 2021: 31 · 2020: 9
FWCI
5.80
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Nature Reviews Cardiology (publishedVersion)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
  • Queen Mary Research Online (Queen Mary University of London) (submittedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Eicosanoids and Hypertension Pharmacology
Keywords
nonsteroidal anti-inflammatory drugs, cardiovascular safety, heart failure, blood pressure, thrombotic complications, COX-2 inhibitors, diclofenac, pain management, analgesics, drug safety
MeSH terms
Anti-Inflammatory Agents, Non-Steroidal, Cardiovascular Diseases, Humans, Middle Aged, Risk, Pain Management

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cardiovascular effects and safety of (non-aspirin) NSAIDs. https://app.cochat.ai/papers/10.1038/s41569-020-0366-z
The paper
Schjerning, A.-M., McGettigan, P., & Gislason, G. (2020). Cardiovascular effects and safety of (non-aspirin) NSAIDs. Nature Reviews Cardiology. https://doi.org/10.1038/s41569-020-0366-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.